The effect of dapsone in steroid-dependent asthma
1991; Elsevier BV; Volume: 87; Issue: 3 Linguagem: Inglês
10.1016/0091-6749(91)90393-3
ISSN1097-6825
AutoresBruce Berlow, Myron Liebhaber, Zeb Dyer, T SPIEGEL,
Tópico(s)Asthma and respiratory diseases
ResumoWe studied the steroid-sparing effect of dapsone in 10 subjects with chronic asthma in a preliminary open trial.Dapsone was chosen because it inhibits neutrophil function and possesses anti-injlammatory effects in a variety of disorders.The study group consisted of 10 subjects with stable, steroid-dependent asthma, aged 23 to 80 years, with normal glucose6phosphate dehydrogenase levels.Average daily baseline prednisone dose ranged from 5 to 60 mg.Dapsone, 100 mg, twice daily, by mouth, was started after a l-month baseline period.Baseline steroid dose, symptom scores, and daily peakJlow rates were compared to the latest available I-week period of dupsone treatment.Average cumulative monthly prednisone dose was reduced from 428 mg to 82 mg (p < 0.02).Five of IO patients stopped steroids by month 6 and two additional patients by month 13.Two additional patients demonstrated a coincidental 74% reduction in steroid dose, and one patient demonstrated no response.Clinical parameters remained stable despite steroid reduction.These preliminary data suggest dapsone may have steroid-sparing effects in chronic asthma.(
Referência(s)